Initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension: A case report

<title>Extract</title> For patients with newly diagnosed idiopathic pulmonary arterial hypertension (IPAH) at high risk of death, current guidelines recommend initial triple combination therapy consisting of an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and a parenteral prostacyclin analogue [1].